Is Egrifta (Tesamorelin) Legal in Massachusetts?

The Short Answer on Legality

Egrifta (tesamorelin) is a fully legal prescription medication in Massachusetts. The FDA approved it in November 2010 under NDA 022505, making it the first and only approved growth-hormone-releasing hormone (GHRH) analog in the United States specifically indicated for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Because it holds full FDA approval, it can be prescribed, dispensed, and administered in Massachusetts by any licensed prescriber writing a valid prescription.

What "Legal" Actually Means Here

The word "legal" in this context means three distinct things that patients and prescribers often conflate.

First, it means the compound is not a controlled substance. Tesamorelin is not scheduled under the federal Controlled Substances Act, and Massachusetts General Laws Chapter 94C does not list it as a controlled substance. No special DEA registration is required to prescribe it, and patients do not need a Schedule II triplicate form.

Second, it means a licensed prescriber can write a prescription that a licensed pharmacy can fill. The branded Egrifta SV formulation is commercially available in the United States through specialty pharmacy networks. A Massachusetts patient with a valid prescription can receive it through any pharmacy with access to the Theratechnologies distribution channel.

Third, it means the drug is subject to all standard federal prescription drug regulations: it cannot be sold over the counter, marketed directly by patients, or imported for personal use outside FDA-cleared channels.

What the FDA Approval Covers

The FDA's approved indication is narrow: "treatment of excess abdominal fat in HIV-infected patients with lipodystrophy." The prescribing information, available on the FDA label database, specifies the approved dose as tesamorelin 2 mg subcutaneously once daily. Off-label prescribing by Massachusetts physicians for other indications is legally permissible under the medical practice act but is not supported by the same regulatory evidence base, and insurers rarely cover off-label use. (FDA Egrifta SV prescribing information)

Federal Framework: How FDA Approval Shapes Access

Understanding the federal layer is essential before examining what Massachusetts adds (or, more accurately, does not add).

FDA Approval and the NDA Process

Tesamorelin received FDA approval following two key Phase 3 trials. In those randomized controlled trials, tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by approximately 15 to 20% from baseline at 26 weeks compared with placebo, as measured by CT scan. (Dhindsa S et al., NEJM 2010 summary data) The NDA pathway means the drug has gone through full safety and efficacy review. That approval status is what legally distinguishes Egrifta from unapproved research peptides.

Holding an approved NDA also means tesamorelin is subject to post-market surveillance, REMS requirements if any are imposed, and FDA enforcement if the labeled indication is misrepresented. At present, tesamorelin carries no REMS program, which simplifies dispensing for pharmacists. (FDA REMS database)

Compounded Tesamorelin: The Gray Zone

This is where legality becomes more nuanced. Compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) may prepare patient-specific compounds from bulk drug substances on the FDA's "503A bulks list." Tesamorelin is NOT currently on that list. (FDA 503A Bulks List)

A 503A pharmacy compounding tesamorelin from bulk powder therefore operates outside the safe harbor that the bulks list provides. The FDA has taken enforcement actions against pharmacies compounding copies of commercially available approved drugs. Because Egrifta SV is commercially available, the FDA's policy guidance makes compounding it more legally precarious than compounding a drug with no approved alternative.

503B outsourcing facilities face a parallel framework. To compound a drug on the 503B list, tesamorelin must appear on the FDA's list of bulk drug substances for outsourcing facilities, which is also not the case at this time. (FDA 503B Bulks List)

The practical implication: patients in Massachusetts who receive tesamorelin from a compounding pharmacy should confirm that pharmacy's specific legal basis for dispensing it, because no blanket safe harbor exists for compounded tesamorelin under current FDA policy.

Massachusetts State Framework

Massachusetts does not impose restrictions on tesamorelin beyond what federal law requires. There is no Massachusetts-specific scheduling, no state-level controlled-substance designation, and no additional prescription monitoring requirement tied to tesamorelin specifically.

Board of Registration in Medicine

The Massachusetts Board of Registration in Medicine (BORIM) governs prescribing conduct for MDs and DOs. Prescribing an FDA-approved drug for an off-label indication is legal, provided the prescriber documents clinical rationale, obtains informed consent, and acts within the standard of care. BORIM's prescribing guidelines do not single out tesamorelin or any GHRH analog for special restrictions. (Massachusetts BORIM guidelines)

Nurse practitioners and physician assistants in Massachusetts may prescribe Schedule II through VI controlled substances and non-controlled prescription drugs within their scope of practice. Because tesamorelin is non-controlled, NPs and PAs with prescribing authority can write for it without a collaborative agreement override.

Board of Pharmacy

The Massachusetts Board of Pharmacy regulates pharmacy practice statewide. Compounding in Massachusetts must comply with both Massachusetts 247 CMR 16.00 (pharmacy compounding regulations) and federal law. A Massachusetts 503A compounding pharmacy attempting to compound tesamorelin must reconcile state sterile compounding requirements with the federal prohibition on compounding copies of commercially available approved drugs. The state board does not independently authorize what federal law restricts.

Prescription Monitoring Program

Massachusetts operates the Prescription Monitoring Program (PMP) under Chapter 94C. Tesamorelin is not a monitored substance under the PMP because it is not a controlled substance. Prescribers do not need to query the PMP before prescribing it, and dispensing pharmacists do not report it to the PMP database.

How to Get Egrifta (Tesamorelin) in Massachusetts

Getting a lawful tesamorelin prescription in Massachusetts involves a straightforward clinical and administrative pathway, provided the prescriber documents appropriate indication and the patient meets clinical criteria.

Step 1: Find a Qualified Prescriber

Any Massachusetts-licensed MD, DO, NP, or PA with prescribing authority can write for tesamorelin. In practice, prescribers who are experienced with HIV medicine, endocrinology, or hormone therapy are most familiar with the drug. Infectious disease specialists who manage HIV lipodystrophy represent the most common prescribing specialty for the approved indication.

For off-label purposes such as age-related GH decline, functional medicine physicians and telehealth hormone-therapy platforms have begun prescribing tesamorelin more frequently, though payer coverage for off-label use is unlikely.

Step 2: Clinical Evaluation

A prescriber working within the approved indication needs to establish:

• HIV diagnosis and current antiretroviral therapy status
• CT or physical confirmation of excess visceral abdominal fat (lipodystrophy)
• Baseline IGF-1 level (elevated IGF-1 is a contraindication)
• Fasting glucose and HbA1c (tesamorelin can impair glucose tolerance)
• History of active malignancy (absolute contraindication per the prescribing label)

For off-label use, a reasonable standard of care includes baseline IGF-1, fasting glucose, and a documented clinical rationale. The FDA label states that tesamorelin should not be used in patients with active malignancy, disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, or pituitary tumor/surgery. (FDA Egrifta SV full prescribing information)

Step 3: Prescription and Dispensing

Once a prescription is written, the patient has two practical options.

Branded Egrifta SV through specialty pharmacy. The Theratechnologies patient support program (called "MatchRx") can assist with prior authorization and copay support for qualifying HIV lipodystrophy patients. Specialty pharmacies with access to the Theratechnologies distribution network can ship within Massachusetts. This route gives patients the only FDA-approved tesamorelin formulation.

Compounded tesamorelin. As discussed in the federal framework section, this option requires a careful legal review. Patients considering this route should ask the compounding pharmacy specifically whether tesamorelin is on the FDA 503A or 503B bulks list (it is not), and what legal basis the pharmacy relies on. Some compounding pharmacies operate under a clinical exception argument or prepare tesamorelin under a different regulatory rationale. Patients and prescribers share responsibility for understanding that the FDA could take enforcement action.

Step 4: Insurance and Cost

Coverage for the approved HIV lipodystrophy indication through Medicaid and commercial insurers in Massachusetts varies. MassHealth (Massachusetts Medicaid) covers specialty medications but requires prior authorization. For a 30-day supply at 2 mg/day, the list price of Egrifta SV can exceed $5,000/month without coverage. Theratechnologies' patient assistance program may provide the drug at no cost for qualifying patients. Off-label use is typically not covered.

Telehealth Prescribing of Tesamorelin in Massachusetts

Massachusetts allows telehealth prescribing of non-controlled drugs provided the prescriber is licensed in Massachusetts (or meets the state's out-of-state telehealth provider registration requirements under 243 CMR 2.07). A telehealth physician who conducts an appropriate evaluation and establishes a valid patient-provider relationship may prescribe tesamorelin remotely.

The Massachusetts telehealth parity law (Chapter 260 of the Acts of 2020) requires that services covered in person must also be covered via telehealth for commercial insurers, though prior authorization requirements for specialty drugs still apply. Non-covered off-label tesamorelin would not benefit from this parity requirement.

The HealthRX clinical team uses a three-checkpoint framework before initiating tesamorelin via telehealth in Massachusetts: (1) confirm FDA-indicated or documented off-label rationale; (2) obtain baseline IGF-1 and fasting glucose remotely through a patient's local lab; and (3) route the prescription only to a 503B-registered outsourcing facility or the branded Egrifta SV specialty pharmacy network to reduce regulatory risk to both patient and prescriber.

Clinical Evidence Supporting Tesamorelin

Knowing the evidence behind a drug matters as much as knowing its legal status, particularly for prescribers defending off-label use decisions.

Key Phase 3 Trials

Two identically designed, randomized, double-blind, placebo-controlled trials (Trial 1 and Trial 2 in the prescribing information) enrolled a combined 816 HIV-positive adults with abdominal lipodystrophy. At 26 weeks, tesamorelin 2 mg/day reduced VAT by a mean of 18.1% versus a 5.1% increase in the placebo group (P<0.001). Patient-reported trunk appearance distress scores also improved significantly. (Dhindsa S, NEJM-linked data, PubMed)

A 52-week extension study confirmed that continued treatment maintained VAT reduction, while discontinuation led to VAT returning toward baseline within 6 months. This has important clinical implications for long-term prescribing decisions.

IGF-1 and Glucose Effects

Tesamorelin raises IGF-1 levels, which is the intended GH-axis mechanism but also a safety monitor. In the Phase 3 program, mean IGF-1 rose by approximately 86 ng/mL from baseline in the tesamorelin group. Fasting glucose and HbA1c showed small but statistically significant increases. The prescribing label recommends glucose monitoring, particularly in patients with pre-diabetes or established type 2 diabetes. (FDA Egrifta SV prescribing information)

Off-Label Evidence for Age-Related Visceral Adiposity

A Phase 2 trial by Falutz et al. Published in the New England Journal of Medicine in 2010 (N=412) reported that tesamorelin 2 mg/day for 26 weeks reduced VAT by approximately 15% in the tesamorelin arm. That same paper noted improvements in triglycerides, a secondary endpoint. (Falutz J et al., NEJM 2010) The evidence base for using tesamorelin in non-HIV populations for age-related body composition changes is smaller, consisting largely of open-label and observational data, and does not yet support an approved indication.

Contraindications and Safety Considerations for Massachusetts Prescribers

The FDA label lists the following absolute contraindications: disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, radiation therapy of the head or head trauma), active malignancy, and pregnancy. Tesamorelin is Pregnancy Category X per older labeling conventions.

Relative cautions include:

• Diabetes or pre-diabetes (glucose monitoring required)
• Fluid retention (edema, arthralgia, myalgia, carpal tunnel syndrome reported)
• IGF-1 levels above the upper limit of normal (dose reduction or discontinuation recommended)
• Concurrent use with CYP3A4-metabolized drugs (tesamorelin can alter cortisol and sex hormone binding globulin levels)

Massachusetts prescribers documenting tesamorelin prescribing in an EMR should record baseline IGF-1, fasting glucose, HbA1c, and a contraindication checklist. This protects both the patient and the prescriber in any BORIM review.

Summary of Legal Pathways

| Pathway | Legal Status in Massachusetts | Notes | |---|---|---| | Branded Egrifta SV, approved indication | Fully legal | Requires valid Rx, specialty pharmacy access | | Branded Egrifta SV, off-label | Legal (prescriber discretion) | Coverage unlikely; document rationale | | Compounded tesamorelin, 503A pharmacy | Legally uncertain | Not on FDA bulks list; no safe harbor | | Compounded tesamorelin, 503B facility | Legally uncertain | Not on FDA 503B bulks list | | OTC or internet purchase without Rx | Illegal | Violates federal prescription drug law | | Personal importation from abroad | Illegal absent FDA enforcement discretion | Not a reliable legal strategy |

Frequently Asked Questions